In the ever-evolving field of immuno-oncology, understanding the functional landscape of tumor-infiltrating lymphocytes (TILs) is critical for advancing TIL-based therapies. At Creative Biolabs, our flow cytometry-based phenotypic profiling is a robust, high-resolution technique that provides precise, quantitative data, allowing for a comprehensive view of phenotypic and functional heterogeneity within TIL populations.
Tumor-infiltrating lymphocytes (TILs) consist of a diverse subset of immune cells that penetrate tumor tissues. Each subset carries unique biomarkers that not only define their functional roles but also their interactions with tumors and other immune cells. For instance, CD3, CD4, and CD8 markers are essential for identifying T cells, while CD19 is used for B cells. The presence of regulatory T cells, often marked by CD25 and FoxP3, is of particular interest due to their immune-suppressive functions.
Fig.1 Some types of TILs and their function in cancer.1
The heterogeneity and complexity of TILs necessitate advanced technologies to accurately characterize these cells. Flow cytometry stands out as a powerful analytical tool, capable of immunophenotyping and identifying functional states of immune cells through surface and intracellular marker detection.
At Creative Biolabs, we provide comprehensive TIL phenotypic profiling services that enable researchers to gain deep insights into TILs, offering precise characterization of immune cell populations within the tumor microenvironment. Our experts employ state-of-the-art flow cytometry techniques to conduct comprehensive phenotypic profiling of TILs. Our Flow cytometry stands out as a powerful tool, enabling the simultaneous analysis of multiple parameters at the single-cell level. This precision allows for an in-depth exploration of the cell surface and intracellular markers that define TIL subsets and their functional states. Utilizing advanced flow cytometry techniques, we provide detailed analyses of cell surface markers, functional responses, and immune phenotypes, empowering studies in cancer immunology and therapeutic development.
Our service provides an in-depth analysis of TIL subsets, leveraging a broad panel of biomarkers to identify and characterize a wide array of immune cells present within the tumor. This includes the evaluation of activation markers, exhaustion markers, and other relevant antigens.
Utilizing state-of-the-art flow cytometry technology, our service ensures high sensitivity and specificity in detecting various TIL subsets. This precision allows for accurate quantification and phenotyping, which are crucial for effective immunological assessment and therapeutic decision-making.
With the flexibility to handle large sample sizes efficiently, our service is suitable for various research scales, from small basic research projects to extensive clinical studies. This capability is pivotal for clinical trials and large-scale studies, where timely data acquisition is crucial.
With multiparameter flow cytometry, we assess numerous markers simultaneously, allowing for a comprehensive view of phenotypic and functional heterogeneity within TIL populations.
Partner with us to enhance your research and unlock the potential of TIL profiling in advancing cancer treatment strategies. Please contact us to learn more about our flow cytometry solutions and how we can support your TIL therapy projects.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION